|Mr. John V. Oyler||Co-Founder, Exec. Chairman & CEO||1.58M||N/A||1968|
|Dr. Xiaobin Wu Ph.D.||Pres, COO & GM of China||1.13M||N/A||1963|
|Dr. Xiaodong Wang||Co-Founder & Non-Exec. Director||4M||N/A||1963|
|Dr. Heng Liang||CFO & Chief Strategy Officer||694.61k||7.79M||1963|
|Dr. Edna Huang M.D.||Chief Medical Officer of Hematology||705.49k||9.03M||1973|
|Mr. Daniel Maller||VP of Fin. & Accounting||N/A||N/A||N/A|
|Mr. Michael Garvey||Global Head of Technical Operations||N/A||N/A||1973|
|Mr. Craig West CFA||Sr. Director of Investor Relations||N/A||N/A||N/A|
|Mr. Scott Samuels||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
|Ms. Diana Lee Francis||VP and Global Head of Quality & Regulatory Compliance||N/A||N/A||N/A|
BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.
BeiGene, Ltd.’s ISS Governance QualityScore as of April 30, 2021 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 6.